EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry

Deborah Elstein iD, Nadia Belmatoug iD, Bruno Bembi, Patrick Deegan iD, Diego Fernandez-Sasso, Pilar Giraldo iD, Özlem Göker-Alpan iD, Derralynn Hughes, Heather Lau iD, Elena Lukina, Shoshana Revel-Vilk iD, Ida Vanessa D Schwartz und 6 weitere

Journal of Clinical Medicine · 19.06.2024 · 13 (12) · 3588

DOI: 10.3390/jcm13123588 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 19.06.2024. Verfasst von Deborah Elstein und 17 weiteren Autor:innen. Beteiligte Einrichtung: Takeda Pharmaceuticals International AG, 8152 Zurich, Switzerland. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Takeda (Switzerland), Takeda Pharmaceuticals International AG. Takeda Development Center Americas, Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-term patient registries are important for evaluating treatment outcomes in patients with rare diseases, and can provide insights into natural disease history and progression in real-world clinical practice. Initiated in 2010, the Gaucher Outcome Survey (GOS) is an ongoing, international, multicenter, observational registry (ClinicalTrials.gov Identifier: NCT03291223) for patients with a diagnosis of Gaucher disease (GD), irrespective of treatment type or status, with a primary objective to monitor safety and long-term effectiveness of velaglucerase alfa.

Methods

Here, we evaluated the GOS population 12 years after the registry initiation.

Results

As of 25 February 2023, 2084 patients enrolled in the GOS and 1643 received GD-specific treatment. Patients exhibited broad heterogeneity at baseline: age of diagnosis (0 to 85.3 years), hemoglobin concentrations (150 g/L), platelet counts (450 × 109/L), and liver and spleen volumes. Most patients treated with enzyme replacement therapy or substrate reduction therapy reported improvements in clinical parameters within 1 year of treatment initiation, maintained over the course of treatment up to 12 years, whereas untreated patients had baseline values closer to standard reference thresholds and showed stability over time.

Conclusion

The 12-year data from the GOS confirm the impact of long-term treatment with GD-specific agents and offer insights into disease progression and outcomes in a real-world setting.

Schlagwörter

Stichwörter der Autor:innen

ERTGOSGaucher diseaseenzyme replacement therapyregistryvelaglucerase alfa

Autor:innen und Institutionen

  • Takeda Pharmaceuticals International AG, 8152 Zurich, Switzerland.
  • Assistance-Publique Hôpitaux de Paris Nord, Université Paris Cité, 92110 Clichy, France.
  • Centre for Lysosomal Diseases, Academic Medical Centre Hospital of Udine, 33100 Udine, Italy.
  • Department of Medicine, Addenbrookes Hospital, University of Cambridge, Cambridge CB2 0QQ, UK.
  • Instituto William Osler, Buenos Aires C1425 BRI, Argentina.
  • CIBER de Enfermedades Raras, IIS Aragon, 50009 Zaragoza, Spain.

ORCID-Profile: Deborah Elstein, Nadia Belmatoug, Patrick Deegan, Pilar Giraldo, Özlem Göker-Alpan, Heather Lau, Shoshana Revel-Vilk, Majdolen Istaiti, Ari Zimran

Förderung

  • Takeda (Switzerland)
  • Takeda Pharmaceuticals International AG. Takeda Development Center Americas, Inc.

Zitieren

APA

Elstein, D., Belmatoug, N., Bembi, B., Deegan, P., Fernandez-Sasso, D., Giraldo, P., Göker-Alpan, Ö., Hughes, D., Lau, H., Lukina, E., Revel-Vilk, S., Schwartz, I. V. D., Istaiti, M., Botha, J., Gadir, N., Schenk, J., Zimran, A., & GOS Study Group (2024). Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry. Journal of Clinical Medicine, 13(12), 3588. https://doi.org/10.3390/jcm13123588

Vancouver

Elstein D, Belmatoug N, Bembi B, Deegan P, Fernandez-Sasso D, Giraldo P, et al. Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry. Journal of Clinical Medicine. 2024;13(12):3588. doi:10.3390/jcm13123588

BibTeX
@article{Elstein2024,
  author = {Elstein, Deborah and Belmatoug, Nadia and Bembi, Bruno and Deegan, Patrick and Fernandez-Sasso, Diego and Giraldo, Pilar and Göker-Alpan, Özlem and Hughes, Derralynn and Lau, Heather and Lukina, Elena and Revel-Vilk, Shoshana and Schwartz, Ida Vanessa D and Istaiti, Majdolen and Botha, Jaco and Gadir, Noga and Schenk, Jörn and Zimran, Ari and GOS Study Group, GOS Study Group},
  title = {Twelve Years of the Gaucher Outcomes Survey (GOS): Insights, Achievements, and Lessons Learned from a Global Patient Registry},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {12},
  pages = {3588},
  doi = {10.3390/jcm13123588}
}
Kostenlos starten →